Betibeglogene autotemcel (beti-cel) gene therapy for the treatment of Transfusion-Dependent β-Thalassemia (TDT): Updated long-term efficacy and safety results

被引：0
|
作者：
Kulozik, A. E. [1 ]
Thuret, I [2 ]
Thompson, A. A. [3 ]
Kwiatkowski, J. L. [4 ]
Porter, J. B. [5 ]
Hongeng, S. [6 ]
Yannaki, E. [7 ]
Sauer, M. G. [8 ]
Thrasher, A. J. [9 ]
Lal, A.
Du, L. [10 ]
Colvin, R. A. [11 ]
Walters, M. C. [12 ]
Locatelli, F. [13 ]
机构：
[1] Heidelberg Univ, Univ Med Ctr Children & Adolescents, Heidelberg, Germany
[2] Marseille Univ, Dept Pediat Hematol, Marseille, France
[3] Feinberg Sch Med, Hematol Sect, Chicago, IL USA
[4] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA USA
[5] UCL, Dept Haematol, London, England
[6] Ramathibodi Hosp, Dept Pediat, Fac Med, Bangkok, Thailand
[7] G Papanicolaou Hosp, Hematol Dept Hematopoiet Cell Transplantat Unit, Gene & Cell Therapy Ctr, Thessaloniki, Greece
[8] Hannover Med Sch, Pediat Hematol & Oncol, Hannover, Germany
[9] Great Ormond St Hosp Sick Children, London, England
[10] UCSF Benioff Childrens Hosp, Oakland, CA USA
[11] Bluebird Bio Inc, Cambridge, England
[12] Univ Calif San Francisco, San Francisco, CA 94143 USA
[13] Osped Pediat Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V293
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [21] Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study
    Zahid Ali
    Mohammad Ismail
    Inayat Ur Rehman
    Gulab Fatima Rani
    Muhammad Ali
    Muhammad Tariq Masood Khan
    Scientific Reports, 13
  • [22] The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan
    Chang, Hsiu-Hao
    Lu, Meng-Yao
    Peng, Steven Shinn-Forng
    Yang, Yung-Li
    Lin, Dong-Tsamn
    Jou, Shiann-Tarng
    Lin, Kai-Hsin
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 1945 - 1952
  • [23] The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan
    Hsiu-Hao Chang
    Meng-Yao Lu
    Steven Shinn-Forng Peng
    Yung-Li Yang
    Dong-Tsamn Lin
    Shiann-Tarng Jou
    Kai-Hsin Lin
    Annals of Hematology, 2015, 94 : 1945 - 1952
  • [24] Interim Results of Betibeglogene Autotemcel Gene Therapy in Pediatric Patients With Transfusion-dependent B-Thalassemia (TDT) Treated in The Phase 3 Northstar-2 (HGB-207) And Northstar-3 (HGB-212) Studies
    Thuret, Isabelle
    Thompson, Alexis
    Kwiatkowski, Janet
    Porter, John
    Hongeng, Suradej
    Yannaki, Evangelia
    Kulozik, Andreas
    Sauer, Martin
    Thrasher, Adrian
    Lal, Ashutosh
    Guo, Ruiting
    Liu, Weijian
    Colvin, Richard
    Walters, Mark
    Locatelli, Franco
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 64 - 65
  • [25] A Retrospective Long-Term Study on Age at Menarche and Menstrual Characteristics in 85 Young Women with Transfusion-Dependent β-Thalassemia (TDT)
    Di Maio, Salvatore
    Marzuillo, Pierluigi
    Mariannis, Demetris
    Christou, Soteroula
    Ellinides, Andreas
    Christodoulides, Costantinos
    de Sanctis, Vincenzo
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
  • [26] Safety Following Autologous Transplantation with Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in the Northstar Hgb-204 Study
    Walters, Mark C.
    Kwiatkowski, Janet L.
    Rasko, John E. J.
    Hongeng, Suradej
    Schiller, Gaol J.
    Anurathapan, Usanarat
    Cavazzana, Marina
    Ho, Phoebe Joy
    von Kalle, Christof
    Kletzel, Morris
    Leboulch, Philippe
    Vichinsky, Elliot P.
    Deary, Briana
    Asmal, Mohammed
    Thompson, Alexis A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S66 - S66
  • [27] Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent β-Thalassemia
    Schneiderman, Jennifer
    Thompson, Alexis A.
    Walters, Mark C.
    Kwiatkowski, Janet L.
    Kulozik, Andreas E.
    Sauer, Martin G.
    Porter, John B.
    Thuret, Isabelle
    Hongeng, Suradej
    Lal, Ashutosh
    Thrasher, Adrian J.
    Yannaki, Evangelia
    Elliot, Heidi
    Tao, Ge
    Liu, Weijian
    Colvin, Richard A.
    Locatelli, Franco
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S87 - S88
  • [28] Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study
    Kwiatkowski, Janet L.
    Thompson, Alexis A.
    Rasko, John E. J.
    Hongeng, Suradej
    Schiller, Gary J.
    Anurathapan, Usanarat
    Cavazzana, Marina
    Ho, P. Joy
    Schmidt, Manfred
    Kletzel, Morris
    Vichinsky, Elliott P.
    Deary, Briana
    Chen, Ying
    Petrusich, Alexandria
    Walters, Mark C.
    BLOOD, 2019, 134
  • [29] LONG-TERM INTRAVENOUS DEFEROXAMINE TREATMENT FOR NONCOMPLIANT TRANSFUSION-DEPENDENT BETA-THALASSEMIA PATIENTS
    TAMARY, H
    GOSHEN, J
    CARMI, D
    YANIV, I
    KAPLINSKY, C
    COHEN, IJ
    ZAIZOV, R
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1994, 30 (08): : 658 - 664
  • [30] Interim results of betibeglogene autotemcel gene-additiontherapy in pediatric patients with transfusion-dependent β-thalassemia (TDT) treated in the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies
    Kulozik, A. E.
    Kunz, J.
    Thuret, I
    Thompson, A. A.
    Kwiatkowski, J. L.
    Porter, J. B.
    Hongeng, S.
    Yannaki, E.
    Sauer, M. G.
    Thrasher, A. J.
    Lal, A.
    Guo, R.
    Colvin, R. A.
    Walters, M. C.
    Locatelli, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 8 - 8
12345